This article is more than 5 years old. Information may no longer be current.

Emixustat from Acucela granted orphan drug designation for Stargardt disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has granted orphan drug designation to a drug candidate for the treatment of Stargardt disease, Acucela announced in a press release.

Acucela, which is a wholly owned subsidiary of Kubota Pharmaceutical Holdings, has been developing emixustat hydrochloride for the treatment of Stargardt disease, according to the release.

“We are very pleased to receive FDA’s orphan drug designation for emixustat to treat Stargardt disease,” Ryo Kubota, MD, PhD, chairman, president and CEO of Acucela, said in the release. “We are actively advancing the development of emixustat to address this unmet medical need.”